Rentabilitas dodolan miturut bathi resik Xilio Therapeutics, Inc. (XLO)

Tandha merek Xilio Therapeutics Inc (XLO)

Strong recognition within the scientific community and the authoritative image of Xilio Therapeutics, Inc. (XLO) are driving growth, which, upon reviewing the chart on GURU.Markets, is reflected in the revenue margin indicator, where the latest value is recorded as -20.90. The business relies on the creation of unique proteins to combat cancer in the US. In the future, patents will ensure high profits due to the low-cost synthesis of doses.

XLO: Rentabilitas resik perusahaan xiliotx.com 04.07.2022 - 20.11.2026

Rincian analitis perusahaan Xilio Therapeutics, Inc.

- nilai pasar lan prakiraan target analis:
Ringkesan analitik perusahaan:Xilio - XLO
Barang unggulan xiliotx.com

Specialized cold chain costs for direct drug delivery directly impact the net sales margins of Xilio Therapeutics, Inc. (XLO). This indicator determines the proportion of revenue converted into final profit after deducting all expenses. The calculation is based on the ratio of net income to total sales volume. An upward trend confirms operational efficiency and the scalability of the business model. Investors should note that sharp fluctuations in this metric may signal hidden financial risks.

Analisis pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)